Sonnet BioTherapeutics’ merger with Hyperliquid Strategies Inc. has sent ripples across the digital asset landscape, particularly for HYPE token holders. The $1 billion dollar deal transforms Sonnet from […]
HYPE Price Poised for $50 Rally After Sonnet’s Major Merger Approval
HYPE price is seeing renewed interest after a recent rebound from lows. This surge follows the positive news of Sonnet’s $1 billion digital asset merger approval, boosting overall […]
Sonnet Merged: $1 Billion HYPE Digital Asset Treasury in Focus
After a lengthy delay, Sonnet BioTherapeutics’ shareholders have approved the company’s merger, paving the way for a significant shift into the booming Web3 world. This landmark decision allows […]
Sonnet Stockholders Approve Merger with Hyperliquid Strategies
Sonnet BioTherapeutics Holdings, Inc. shareholders have approved the merger with Hyperliquid Strategies Inc and Rorschach I LLC. This move aligns Sonnet’s oncology focus with its FHAB drug platform […]
Sonnet Delays Merger Vote, Targeting a $1 Billion Digital Asset Venture
Sonnet BioTherapeutics has announced a delay in its merger vote with Hyperliquid Strategies Inc. and Rorschach I LLC to December 2025. This move seeks to secure majority shareholder […]